Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: p62 (SQSTM1) (total)

Search for Biomarkers

Analyte:

p62 (SQSTM1) (total)

Platform:

Status:

Experienced Running

Biological or Clinical Significance:

The p62/Sequestosome 1 (p62, SQSTM1) protein is a scaffold protein that binds polyubiquitin chains and forms a cytoplasmic “sequestosome” where ubiquitinated, mis-fold, or non-functional proteins are stored for autophagic degradation. Tumor cells often utilize autophagy for survival in low nutrient and hypoxic conditions or in response to cancer treatments. Inhibition of p62 action may enhance chemotherapies by disrupting the pro-survival signaling cascades that work to maintain cell integrity and limit apoptosis. P62 functions in concert with tumor necrosis factor receptor associated factor 6 to mediate activation of nuclear factor kappa-B signaling pathway in response to upstream signals involving atypical protein kinase C. Over expression or dysregulation of p62 interactions can result in large cytoplasmic aggregates including those found in aggregation diseases affecting the brain and liver.

References:

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies